*************************************

Bio-One Says Q2 Revenue to Exceed $13 Million
Wednesday July 7, 8:57 am ET

ORLANDO, Fla., July 7 /PRNewswire-FirstCall/ -- Bio-One Corporation (OTC Bulletin Board: BICO - News) announced today that its revenue for the second fiscal quarter ended June 30, 2004 will exceed $13 million. The company said it expects operating profits to be approximately $2 million. The company reported no revenues a year ago.
ADVERTISEMENT


Bio-One President and CEO Armand Dauplaise said, "The final numbers for the quarter are not yet in, but at this point it looks as if we are close to our internal projections for the quarter, which means we should report revenues in excess of $13 million. These results reflect the impact of our continuing acquisitions and vertical integration program."

Since September 2003, Bio-One has acquired five companies, which collectively reported 2003 audited revenues of $38 million and operating profits (EBITDA) of $5.8 million. They are:

PNLabs: Acquired September 2003. $1 million nutritional supplements marketer.

American Nutritional Exchange: Acquired 80% interest February 2004. $7.1 million supplements distributor.

Interactive Nutrition International: Acquired March 2004. $12 million manufacturer and distributor of branded supplements.

WeiFang Shengtai Pharmaceuticals: Acquired 51% April 2004. $16.3 million Chinese glucose manufacturer.

Florida Sport Nutrition Distributors: Acquired June 2004. $2 million supplements distributor.

About Bio-One

Bio-One Corporation is a nutritional supplements company serving the preventive and alternative healthcare segments. The company intends to acquire additional businesses in order to provide quality nutraceuticals to consumers through vertical integration of manufacturing, distribution and marketing. Current Bio-One subsidiaries include PNLabs, American Nutritional Exchange, Interactive Nutrition International, Nutrition Sciences Corporation, WeiFang Shengtai Pharmaceuticals Co. Ltd. and ANI Distribution.

Bio-One Corporation is committed to its mission of the continuing pursuit of excellence in serving its customers, suppliers, team members and shareholders. Bio-One is confident that it will accomplish its mission and goals through the application of its management philosophy, which is to treat others the way they would want to be treated themselves.

An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

For investor relations information, contact Frank Hawkins or Julie Marshall, Hawk Associates at (305) 852-2383, email: info@hawkassociates.com. For Bio-One information contact Bob Gartzman at 888-327-4703. Detailed information about Bio-One may be found on the website http://www.bioonecorp.com. Copies of Bio-One press releases, current Level II price quotes, interactive and Java stock charts and other valuable information for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com

Certain statements released by Bio-One Corporation that are forward- looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. These include, but are not limited to, economic, competitive, governmental, technological and other risks detailed in the company's registration statements and periodic reports filed with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

***************************************
PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION, DATED MAY 6, 2004

BIO-ONE CORPORATION
293,384,616 SHARES OF COMMON STOCK

This Prospectus relates to the sale of up to 293,384,616 shares of
Bio-One's common stock by certain persons, who are, or will become, stockholders
of Bio-One. The selling stockholders consist of:

o Cornell Capital Partners, L.P., which intends to sell up to an
aggregate amount of 293,346,154 shares of common stock, which
includes 250,000,000 pursuant to a Standby Equity Distribution
Agreement, 20,000,000 shares of common stock underlying a
convertible debenture, 20,500,000 shares of common stock
underlying warrants and 2,846,154 shares of common stock
issued as a commitment fee pursuant to the Standby Equity
Distribution Agreement.

o Newbridge Securities Corporation, an unaffiliated registered
broker-dealer retained by Bio-One in connection with the
Standby Equity Distribution Agreement, which intends to sell
38,462 shares of common stock issued as a placement agent fee.
******************************************
http://www.sec.gov/Archives/edgar/data/1062431/000111650204001161/bioonesb2amendment.txt

Dear Shareholders:

The past six months at Bio-One have been filled with extreme activity involving acquisitions, a rapidly evolving corporate structure, new hires, additional financing support and related activity. Recently a few of our 2,000 shareholders asked that I provide an expanded update. This is a timely opportunity to update you on our progress, which has been significant.

After much planning, we began this effort to seize the enormous opportunity in the nutritional supplement and natural herbal medicine market. Industry estimates put the size of the market in the range of $58 billion and say it is growing at a rate exceeding 10% annually.

There is major opportunity here because 100 million Americans consume supplements; the industry is highly fragmented and ripe for vertical integration, consolidation and streamlining. Of some 5,000 companies actively competing for market share, our research shows that a majority of these companies are founder-owned with sales under $25 million. This is a situation that begs for vertical integration and consolidation. But it must be done in a coherent, logical manner that will result in a prosperous, well-integrated business generating significant revenues, profits and building solid shareholder value. That is the vision that is driving us. Here is how we are doing.

Acquisitions

We have set strict criteria in targeting acquisition candidates. Our research revealed that 90% of marketing companies outsource their product manufacturing. This meant that approximately 40% of the marketing companies' sales that previously went toward cost of goods sold could be captured by a Bio-One owned manufacturer subsidiary, thus increasing operating profits. Armed with this knowledge we secured sufficient capital to acquire one manufacturer, two distribution companies, two marketing companies and are aggressively pursuing additional marketing companies.

Since last September, we have acquired all or a majority interest of five companies that produced nearly $36 million in audited revenues in 2003 and operating profits (EBITDA) of $5.5 million. These are all companies that we believe will show excellent growth in calendar 2004.

PNLabs: Acquired September 2003. $1 million nutritional supplements marketer.

American Nutritional Exchange: Acquired 80% interest February 2004. $7.1 million supplements distributor.

Interactive Nutrition International: Acquired March 2004. $12 million manufacturer and distributor of branded supplements.

WeiFang Shengtai Pharmaceuticals: Acquired 51% April 2004. $16.3 million Chinese glucose manufacturer.

Florida Sport Nutrition Distributors: Acquired June 2004. $2 million supplements distributor.

We believe these five companies will provide us with increasingly strong operating profits (EBITDA) during 2004. More importantly, these initial five acquisitions lay the firm groundwork for building a strong, profitable, vertically integrated business that will provide important economies of scale. They include all aspects from manufacturing to distribution to marketing at the retail, direct-to-consumer and wholesale levels.

The China Strategy

We currently have signed letters of intent and proposals to acquire 51% interest in four additional Chinese companies representing approximately $56 million in 2003 sales with over $11 million in operating profits (EBITDA).

* $20 million Chinese herbal medicine company in Beijing
* $9 million Chinese herbal medicine company in Heibei Province
* $10 million Chinese herbal medicine company in Guangzhou Province
* $17 million Chinese herbal medicine company in HeNan Province

The closing of these acquisitions is subject to the usual conditions that are a necessary part of any transaction, but at this point we expect to close all four in the third and fourth quarters of 2004.

These acquisitions are part of our rapidly unfolding China strategy aimed at building Chinese operations to $100 million in annual revenues with operating profits (EBITDA) exceeding 20%. Helping to drive this strategy is Mary Xia, a seasoned expert in Chinese and international business who is heading our Chinese operations. Mary has played major roles as a strategic planner and in mergers and acquisitions in both American and Chinese companies since 1982. Prior to working as a financial advisor at Morgan Stanley, Mary served for a number of years as president and CEO of Asia Pacific Securities, a corporate finance advisory business providing counsel and services on strategic planning, IPOs, mergers and acquisitions and international joint ventures. Additionally we have appointed a Director of Operations for mainland China.

Emerging Corporate Structure

Domestically, we have formed two new operating subsidiaries, Nutrition Sciences Corp. and ANI Distribution, and we have hired two proven industry veterans to help run our operating units. Rick Popowitz was appointed as CEO of Nutrition Sciences Corp. Rick is a direct-mail expert, co-founded and was the former CEO of Advanced Nutritional Products, a firm he sold to a publicly traded U.K. company. We also brought on Bob Ramsey, a veteran specialist in retail operations and merchandising, as president of PNLabs. We are increasing our board of directors to seven in 2005 with the addition of a former CEO of a billion dollar company, a former CFO of a billion dollar company and others.

Financing and Capital Structure

This area has been our most difficult challenge as we had a $30 million underwriting commitment withdrawn in June 2002 when a European fund closed their Wall Street office. At that time we also lost acquisitions totaling $60 million in revenues. Since then, we have raised $21.5 million in capital, of which $6.5 million is in equity and $15 million is in a convertible debenture. The share price on the $15 million convertible debenture is based on the price of our stock at three different intervals or we may repay any portion with other capital. We also have received a commitment for the purchase of 20 million shares at $.75 per share. This second $15 million is in warrants that expire March 31, 2006. Additionally, we have an equity line of $50 million. To date all funds and the equity line have come from Cornell Capital Partners, a U.S. hedge fund.

The first $15 million was used to close the acquisitions in March, April and June. The second $15 million, if utilized, would be used to continue our development plan.

We are now in discussion with certain investment funds and accredited investors regarding longer-term capital, which would be used to continue our acquisitions strategy and repay some or all of the convertible debenture. We are receiving sufficient interest from capital sources domestically and internationally to believe we will be successful.

We currently have approximately 70 million shares issued and outstanding of which approximately 60 million are in the float. In the event that we are faced with excessive dilution in the next 12 to 18 months, we will give serious consideration to a share buyback. However, we will not consider a stock reverse split.

Looking Forward

I anticipate that the next two quarters will be very active for us. We have numerous initiatives that we are actively pursuing.

Although the final numbers are not yet available and have not been audited, it looks as though we will report revenue of approximately $13 million for our second quarter that ends June 30, 2004 and operating profits (EBITDA) in the range of 15%. By year-end, we expect to show annualized revenue in the $60 to $80 million range not including any acquisitions that we will consummate during the fourth quarter. We are continuing to work with Health Business Partners, the leading mergers and acquisition advisor in our industry. Their assignment is to help identify additional acquisitions that would grow Bio-One revenues to exceed $200 million annualized by the end of 2005 with operating profits (EBITDA) in the 15% to 20% range.

Later in 2004, we are planning to apply for listing on the American Stock Exchange. During 2005, we are planning to spin off Bio-One China and apply for a separate listing on the Nasdaq. At that point, our stock would be trading on two exchanges.

This is the bottom line for those who are evaluating whether Bio-One is the investment vehicle that best fits their individual goals. During the first six months of 2004 we have gone from no revenues, no profits, few assets and little working capital to annualized revenues approaching $60 million with operating profits (EBITDA) in the 15% range and assets exceeding $30 million. As of June 28, 2004, we have increased our share bid and ask price by 36% compared to December 31, 2003. You may be unaware that I have personally purchased more than one million shares through the market and I am the largest single shareholder.

This is solid evidence that my interests are closely tied to those of our shareholders. Rest assured we are doing everything we can to build a company that will produce strong shareholder value along with increasing revenues and profits.

In the meantime, we are committed to the continuing pursuit of excellence in serving our customers, our suppliers, our team members and our shareholders. We fully intend to accomplish our mission and goals through the application of our management philosophy based on treating others the way we want to be treated.

Thank you for your support.

Armand Dauplaise
President and CEO
June 29, 2004

An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

For investor relations information, contact Frank Hawkins or Julie Marshall, Hawk Associates at (305) 852-2383, email: info@hawkassociates.com. For Bio-One information contact Bob Gartzman at 888-327-4703. Detailed information about Bio-One may be found on the website http://www.bioonecorp.com. Copies of Bio-One press releases, current Level II price quotes, interactive and Java stock charts and other valuable information for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com.

Certain statements released by Bio-One Corporation that are forward- looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. These include, but are not limited to, economic, competitive, governmental, technological and other risks detailed in the company's registration statements and periodic reports filed with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Bio-One Corporation

ORLANDO, Fla., Jul 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- Bio-One Corporation (BICO) announced today that it has received an equity investment commitment for $10 million to be used for acquisitions in China.

A Hong Kong-based investor has agreed to pay $1.00 per share for convertible preferred stock, convertible to common after a one-year holding period. Closing on the transaction is anticipated within the next 45 days. The funds will be allocated for acquisitions that represent 2003 revenues of approximately $56 million and 2003 operating profits (EBITDA) of approximately $11 million.

Bio-One President and CEO Armand Dauplaise said, "These acquisitions are part of our rapidly unfolding China strategy aimed at building Chinese operations to $100 million in annual revenues with operating profits (EBITDA) exceeding 20%. This capital and the closing of these acquisitions will facilitate our previously announced plans to spin off Bio-One China during 2005 and apply for a separate listing on Nasdaq. The Hong Kong-based investor also has expressed interest in providing additional equity capital to support future growth. Mary Xia, who is heading our Chinese operations, has played a key role in arranging this investment."

Bio-One currently has signed letters of intent and proposals to acquire 51% interest in four Chinese companies representing approximately $56 million in 2003 sales with over $11 million in operating profits (EBITDA).

* $20 million Chinese herbal medicine company in Beijing * $9 million Chinese herbal medicine company in Heibei Province * $10 million Chinese herbal medicine company in Guangzhou Province * $17 million Chinese herbal medicine company in Henan Province

The closing of these acquisitions is subject to the usual conditions that are a necessary part of any transaction. The company says it expects to close all four in the third and fourth quarters of 2004.

In April 2004, Bio-One acquired 51% of WeiFang Shengtai Pharmaceuticals, a $16.3 million Chinese glucose manufacturer.

About Bio-One

Bio-One Corporation is a nutritional supplements company serving the preventive and alternative healthcare segments. The company intends to acquire additional businesses in order to provide quality nutraceuticals to consumers through vertical integration of manufacturing, distribution and marketing. Current Bio-One subsidiaries include PNLabs, American Nutritional Exchange, Interactive Nutrition International, Nutrition Sciences Corporation, WeiFang Shengtai Pharmaceuticals Co. Ltd. and ANI Distribution.

Bio-One Corporation is committed to its mission of the continuing pursuit of excellence in serving its customers, suppliers, team members and shareholders. Bio-One is confident that it will accomplish its mission and goals through the application of its management philosophy, which is to treat others the way they would want to be treated themselves.

An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

For investor relations information, contact Frank Hawkins or Julie Marshall, Hawk Associates at (305) 852-2383, email: info@hawkassociates.com. For Bio-One information contact Bob Gartzman at 888-327-4703. Detailed information about Bio-One may be found on the website http://www.bioonecorp.com. Copies of Bio-One press releases, current Level II price quotes, interactive and Java stock charts and other valuable information for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com

• "A Hong Kong-based investor has agreed to pay $1.00 per share for convertible preferred stock, convertible to common after a one-year holding period."

• "Later in 2004, we are planning to apply for listing on the American Stock Exchange. During 2005, we are planning to spin off Bio-One China and apply for a separate listing on the Nasdaq. At that point, our stock would be trading on two exchanges. "

• "We currently have approximately 70 million shares issued and outstanding of which approximately 60 million are in the float. In the event that we are faced with excessive dilution in the next 12 to 18 months, we will give serious consideration to a share buyback. However, we will not consider a stock reverse split.

• "You may be unaware that I have personally purchased more than one million shares through the market and I am the largest single shareholder. " -CEO

quote:

---

Originally posted by Garfield1981:
I am confused, it closed at $0.084 yesterday. Why the HK investors willing to pay $1.00 per share?

---

* $20 million Chinese herbal medicine company in Beijing
* $9 million Chinese herbal medicine company in Heibei Province
* $10 million Chinese herbal medicine company in Guangzhou Province
* $17 million Chinese herbal medicine company in Henan Province

The closing of these acquisitions is subject to the usual conditions that
are a necessary part of any transaction. The company says it expects to close
all four in the third and fourth quarters of 2004.
In April 2004, Bio-One acquired 51% of WeiFang Shengtai Pharmaceuticals, a
$16.3 million Chinese glucose manufacturer.

About Bio-One
Bio-One Corporation is a nutritional supplements company serving the
preventive and alternative healthcare segments. The company intends to acquire
additional businesses in order to provide quality nutraceuticals to consumers
through vertical integration of manufacturing, distribution and marketing.
Current Bio-One subsidiaries include PNLabs, American Nutritional Exchange,
Interactive Nutrition International, Nutrition Sciences Corporation, WeiFang
Shengtai Pharmaceuticals Co. Ltd. and ANI Distribution.
Bio-One Corporation is committed to its mission of the continuing pursuit
of excellence in serving its customers, suppliers, team members and
shareholders. Bio-One is confident that it will accomplish its mission and
goals through the application of its management philosophy, which is to treat
others the way they would want to be treated themselves.
An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

For investor relations information, contact Frank Hawkins or Julie
Marshall, Hawk Associates at (305) 852-2383, email: info@hawkassociates.com.
For Bio-One information contact Bob Gartzman at 888-327-4703. Detailed
information about Bio-One may be found on the website http://www.bioonecorp.com. Copies of Bio-One press releases, current Level II
price quotes, interactive and Java stock charts and other valuable information
for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com

Certain statements released by Bio-One Corporation that are forward-
looking statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Editors and investors are
cautioned that forward-looking statements involve risk and uncertainties that
may affect the company's business prospects and performance. These include,
but are not limited to, economic, competitive, governmental, technological and
other risks detailed in the company's registration statements and periodic
reports filed with the Securities and Exchange Commission. By making these
forward-looking statements, the company undertakes no obligation to update
these statements for revisions or changes after the date of this release.

SOURCE Bio-One Corporation
-0- 07/13/2004
/CONTACT: Frank Hawkins or Julie Marshall, both of Hawk Associates,
+1-305-852-2383 or info@hawkassociates.com, for Bio-One Corporation; or Bob
Gartzman of Bio-One Corporation, +1-888-327-4703/
/Web site: http://www.bioonecorp.com/
(BICO)

quote:

---

Originally posted by Garfield1981:
It is not moving....

---

OK, so BICO goes to 13 mil revenue as will be announced in the earnings. - Stock drops

We get 10 mill investment cash - Stock drops

Doesn't make sense.

In 45 days we get the yen check - then we start closing on China deals. You can bet Armand is going to close as many of those as he can before Sept 30 to get them on the 4th full quarter.

AMEX and Nasdaq next year. Worse case - I have to wait 2 years to retire instead on one. Bummer ;-)

Long term - this is the one - I can wait so don't really care too much about current price. Just wish I had waited so I could buy many more shares at this price.
........... 5 mil block at .0869 What's up?
- - - - -

GOOD NEWS for BICO getting that purchase of a 5 mil block. It was above the ask because only way buyer could accumulate that many all at once. Its encouraging having a big hitter take such a large position. We now need the market makers to cooperate by moving the bid/ask up.
..............
5,000,000 shares x .0869 = $434,500
That ain't chicken feed, so maybe this stock won't turn into chicken umm droppings.

COMMON STOCK OUTSTANDING 59,515,870 shares
BEFORE THE OFFERING(1)

COMMON STOCK OUTSTANDING 352,900,486
AFTER THE OFFERING(2)

13 million in revenue is .27 a share of revenue!

I'ld say this thing is oversold!

quote:

---

Originally posted by WinsumLosesum:
Well, apparently I've learned absolutely nothing.

---

Bio-One Corp     (OTC BB: BICO) Last Update: 9:55:00 AM ET Jul 30, 2004  
 
Bio-One Revises Press Release

ORLANDO, Fla., Jul 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- Bio-One Corporation (BICO) announced today that it is revising its press release dated July 13, 2004 concerning an equity investment commitment, as the company incorrectly characterized the current status of the transaction.

Bio-One and a Hong Kong-based investor are currently drafting definitive investment documents that set forth the specific terms of a proposed purchase of shares of Bio-One's preferred stock.

Bio-One's President and CEO Armand Dauplaise said, "We are excited about the interest and potential investment this investor may make in our company. This additional capital would assist us in closing anticipated future acquisitions."

About Bio-One

Bio-One Corporation is a nutritional supplements company serving the preventive and alternative healthcare segments. The company intends to acquire additional businesses in order to provide quality nutraceuticals to consumers through vertical integration of manufacturing, distribution and marketing. Current Bio-One subsidiaries include PNLabs, American Nutritional Exchange, Interactive Nutrition International, Nutrition Sciences Corp. and WeiFang Shengtai Pharmaceuticals Co. Ltd.

Bio-One Corporation is committed to its mission of the continuing pursuit of excellence in serving its customers, suppliers, team members and shareholders. Bio-One is confident that it will accomplish its mission and goals through the application of its management philosophy, which is to treat others the way they would want to be treated themselves.

An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

For investor relations information, contact Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 852-2383, email: info@hawkassociates.com. For Bio-One information, contact Bob Gartzman at 888-327-4703. Detailed information about Bio-One may be found on the website http://www.bioonecorp.com. Copies of Bio-One press releases, current Level II price quotes, interactive and java stock charts and other valuable information for investors may be found on the websites http://www.hawkassociates.com and http://www.hawkmicrocaps.com

Certain statements released by Bio-One Corporation that are forward- looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. These include, but are not limited to, economic, competitive, governmental, technological and other risks detailed in the company's registration statements and periodic reports filed with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Bio-One Corporation

Hello

I am a BICO shareholder, and am confused by todays PR.

Are you retracting this statement contained in your 7/13/04 PR, entitled " Bio-One Receives $10 Million Investment Commitment for China":

"A Hong Kong-based investor has agreed to pay $1.00 per share for convertible preferred stock, convertible to common after a one-year holding period."

Bio-One's President and CEO Armand Dauplaise said, "We are excited about the interest and potential investment this investor may make in our company. This additional capital would assist us in closing anticipated future acquisitions."

(My original email is just 2 posts up)

From: fhawk@hawkassociates.com

Date: Sat, 31 Jul 2004 12:31 AM

Yes. The deal is not yet concluded. Frank Hawkins

ORLANDO, Fla., Aug 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Bio-One Corporation (BICO) reported today consolidated net sales of $10,927,674 in the second quarter ended June 30, 2004 compared with no revenue in the second quarter of 2003. The company said it had a net loss of ($276,917) or ($0.04) per share compared with a net loss of ($152,874) or ($0.05) per share in the comparable quarter a year earlier.

For the quarter, the company had operating income of $1,338,511 compared with an operating loss of ($149,657) in the comparable period a year earlier.

For the first six months of 2004, the company reported consolidated net sales of $15,601,178 compared with no sales in the first six months of 2003. The company incurred a net loss of ($4,915,764) or ($0.07) per share compared with a net loss of ($325,317) or ($0.01) per share in the first half of 2003. Operating income for the first six months of 2004 was $1,108,722 versus an operating loss of ($317,318) in the first six months of June 30, 2003.

Armand Dauplaise, chief executive officer of Bio-One said, "Our revenue reflected the sales from our newly acquired subsidiaries PNLabs, American Nutritional Exchange, Interactive Nutrition International and Weifang Shengtai Pharmaceuticals. This was a major gain from a year ago when we did not report any net sales. Our balance sheet has also been considerably strengthened. At the end of the quarter, we had $19.1 million in cash and other current assets compared with cash of only $18,841 a year ago. This significant increase in our cash position is attributable to a draw on our equity line of credit, the sale of a secured convertible debenture, a secured promissory note and the operating performance of our subsidiaries."

About Bio-One

Bio-One Corporation is a nutritional supplements company serving the preventive and alternative healthcare segments. The company intends to acquire additional businesses in order to provide quality nutraceuticals to consumers through vertical integration of manufacturing, distribution and marketing. Current Bio-One subsidiaries include PNLabs, American Nutritional Exchange, ANI Distribution, Interactive Nutrition International, Nutrition Sciences Corp., Healthy Choices Concepts and WeiFang Shengtai Pharmaceuticals Co. Ltd.

Bio-One Corporation is committed to its mission of the continuing pursuit of excellence in serving its customers, suppliers, team members and shareholders. Bio-One is confident that it will accomplish its mission and goals through the application of its management philosophy, which is to treat others the way they would want to be treated themselves.

An investment profile on Bio-One Corporation may be found at http://www.hawkassociates.com/bioone/profile.htm.

Hope it's just a major shake and it flys during lunch!

Good Luck!

God knows MOST of us need one! THis year has been Awful........

MIAMI, Aug. 20, 2004 (PRIMEZONE) -- Stockwire.com Releases its Movers and Shakers List: Bio-One Corp. (OTC BB:BICO.OB - News), West Africa Gold, Inc. (OTC BB:WAGI.OB - News), Cyberonics, Inc. (NasdaqNM:CYBX - News), XM Satellite Radio (NasdaqNM:XMSR - News).
Bio-One Corporation was formed to serve the emerging niche of preventive and alternative healthcare through nutritional supplements. This niche has grown to a multi-billion dollar industry. The market is considered global. The Company's strategy is to build its business through vertical integration of manufacturing, distribution and marketing by selectively acquiring industry leaders in each distribution channel. Bio-One intends to be one of the first to launch its plan by targeting companies under $25 million in annual sales.

This whole market is whacked the past few months.